MUNICH — Long-term oral anticoagulation (OAC) with rivaroxaban (Xarelto, Bayer/Janssen Pharmaceuticals) had no apparent effect on risk for death, myocardial infarction (MI), or stroke in a large ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results